Imatinib Completed Phase 2 Trials for Metastatic Cancers / Prostate Cancer Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00080678Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases
NCT00500110Hormonal Ablation, Imatinib Mesylate and Docetaxel for Patients With Prostate Cancer
NCT00251225A Study of Imatinib and Docetaxel in Prostate Cancer
NCT00427999Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer
NCT00084825Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008